drugset
drugset / Trial / NCT01054144

Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma

NCT01054144 ↗

Phase 2 Completed 27 enrolled H. Lee Moffitt Cancer Center and Research Institute Celgene Corporation · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this research is to estimate the effectiveness of a response adapted approach with the use of the drug, lenalidomide in the treatment of older adults with newly diagnosed standard risk multiple myeloma. This means that participants will be given the study drug, lenalidomide but depending on how they respond to this drug they may also be given dexamethasone and/or prednisone to help with their treatment.

Timeline

Start
2010-01-14
Primary completion
2020-08
Completion
2020-11-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule 10 mg Oral
Subject Dexamethasone Small molecule 20 mg Oral
Subject Dexamethasone Small molecule 40 mg Oral
Subject Lenalidomide Other / unclassified 5 mg Oral
Subject Lenalidomide Other / unclassified 10 mg Oral
Subject Lenalidomide Other / unclassified 15 mg Oral
Subject Lenalidomide Other / unclassified 25 mg Oral
Subject Prednisone Other / unclassified 25 mg Oral
Subject Prednisone Other / unclassified 50 mg Oral
Subject Prednisone Other / unclassified 100 mg Oral

Indications

plasma cell myeloma